Compare AstraZeneca plc (AZN) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Abrdn Physical Platinum Shares ETF — how do they compare? AstraZeneca plc trades at $159.37 (market cap $250.84B), while Abrdn Physical Platinum Shares ETF trades at $15.95. The key difference: AstraZeneca plc pays a 1.97% dividend while Abrdn Physical Platinum Shares ETF pays none, and Abrdn Physical Platinum Shares ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | PPLT | |
|---|---|---|
Market Cap | $250.84B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $209.48 | $25.23 |
52-Week Low | $147.06 | $11.95 |
Enterprise Value | $278.12B | — |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.42, up 0.22% today, amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth to $58.74B in 2025 and net income of $10.23B, supported by a P/E of 24.16 and robust profitability margins. Recent news highlights potential talks with Bristol Myers Squibb, though a senior source denied ongoing discussions (Reuters, 2026-08-05).
The outlook is mixed: solid earnings beats and a 47.5% analyst buy rating support upside, but technical weakness and merger uncertainty pose near-term risks. Long-term growth hinges on execution amid competitive and regulatory pressures, with the stock offering value if merger rumors subside and fundamentals prevail.
PPLT trades at $15.85, up 1.15% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The stock is set for a 1:10 stock split effective May 18, 2026. Recent news highlights platinum's underperformance versus gold and silver, positioning PPLT as a potential catch-up trade in the precious metals sector.
The outlook for PPLT hinges on a potential rebound in platinum prices, supported by positive sentiment from recent geopolitical developments. Key risks include continued commodity price volatility and the ETF's lack of dividend income, which may deter yield-seeking investors despite its strong past performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
